Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
30.41
-0.74 (-2.38%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
99
100
Next >
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector
↗
August 01, 2025
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.
Via
Benzinga
Which S&P500 stocks are gapping on Friday?
↗
August 01, 2025
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via
Chartmill
Moderna CEO Attributes Full-Year Revenue Guidance Reduction To Timing Of Shipments: Retail Pins Hopes On Pipeline After Q2 Beat
↗
August 01, 2025
The vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range.
Via
Stocktwits
Topics
Artificial Intelligence
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
↗
August 01, 2025
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.
Via
Benzinga
Topics
Intellectual Property
Moderna's Earnings: A Preview
↗
July 31, 2025
Via
Benzinga
Top S&P500 movers in Friday's pre-market session
↗
August 01, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Friday?
Via
Chartmill
Moderna (NASDAQ:MRNA) Exceeds Q2 Expectations But Stock Drops
August 01, 2025
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 41.1% year on year to $142 million. On the other hand, the...
Via
StockStory
Moderna Stock Falls Again Amid Lowered Guidance, Job Cuts
↗
August 01, 2025
The biotech reported a smaller-than-expected Q2 loss and revenue decline.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Dow Futures Decline As Trump Unleashes Tariffs Globally: AAPL, AMZN, COIN, RDDT, CVX, XOM Among Stocks To Watch
↗
August 01, 2025
While Dow Jones futures were down 0.94% at the time of writing, the S&P 500 futures fell 0.95%.
Via
Stocktwits
Topics
ETFs
Government
Stocks
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 01, 2025
Via
ACCESS Newswire
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
August 01, 2025
Via
ACCESS Newswire
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
August 01, 2025
Via
Benzinga
Moderna Announces 10% Layoffs Ahead Of Q2 Report: Retail Now Eyes ‘Good Enough’ Earnings
↗
July 31, 2025
CEO Stéphane Bancel said in a note to employees on Thursday that the move is part of the company’s commitment to reduce annual operating expenses by about $1.5 billion by 2027.
Via
Stocktwits
Topics
Artificial Intelligence
Supply Chain
Workforce
Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles
↗
July 31, 2025
Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.
Via
Benzinga
Earnings Scheduled For August 1, 2025
↗
August 01, 2025
Via
Benzinga
Moderna Earnings: What To Look For From MRNA
July 30, 2025
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
Government
World Trade
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
July 30, 2025
Via
ACCESS Newswire
Oscar Health, Surgery Partners, Moderna, Molina Healthcare, and Fortrea Stocks Trade Down, What You Need To Know
July 29, 2025
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending...
Via
StockStory
Uncover the latest developments among S&P500 stocks in today's session.
↗
July 29, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'
↗
July 28, 2025
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken...
Via
Benzinga
Moderna Announces Data to be Presented at ESMO Congress 2025
July 28, 2025
Via
ACCESS Newswire
Down 74% Over the Past Year, Is Moderna Stock a Buy?
↗
July 26, 2025
Via
The Motley Fool
Biotech Is Booming, and This Undervalued REIT Stands to Gain
↗
July 25, 2025
Via
The Motley Fool
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
July 25, 2025
Via
ACCESS Newswire
What's Going On With Moderna Stock Wednesday?
↗
July 23, 2025
Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political uncertainty.
Via
Benzinga
Which S&P500 stocks are moving on Wednesday?
↗
July 23, 2025
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via
Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
↗
July 23, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Wednesday's session: gap up and gap down stock in the S&P500 index
↗
July 23, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.
Via
Chartmill
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know
July 18, 2025
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...
Via
StockStory
Topics
Lawsuit
World Trade
3 of Wall Street’s Favorite Stocks That Fall Short
July 18, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.